| Market Capitalization (Millions $) |
0 |
| Shares
Outstanding (Millions) |
131 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-1 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Burzynski Research Institute Inc is a biomedical research institution located in Houston, Texas. It was founded by Dr. Stanislaw Burzynski in 1976. The institute is primarily focused on researching and developing innovative oncology treatments.
Burzynski Research Institute is best known for its controversial treatment called Antineoplaston therapy. This therapy claims to target and destroy cancer cells by using a combination of naturally occurring peptides and amino acid derivatives. However, the effectiveness and safety of this treatment have been a subject of debate among the medical community.
In addition to Antineoplaston therapy, the institute also conducts research on other treatment methods for various types of cancers, including personalized gene-targeted therapy and targeted chemotherapy. It aims to provide alternative treatment options for patients who have exhausted conventional treatment options.
Over the years, Burzynski Research Institute has faced scrutiny from regulatory authorities and skeptics due to concerns about the scientific validity of its experimental treatments, patient safety, and ethical issues related to its clinical trials. However, it has also garnered support from patients and their families who claim to have experienced positive outcomes from the institute's treatments.
Overall, the Burzynski Research Institute Inc has gained both recognition and controversy for its unconventional cancer treatments and research efforts.
Company Address: 9432 Katy Freeway Houston 77055 TX
Company Phone Number: 335-5697 Stock Exchange / Ticker: NONE BZYR
|
0.000%
9.21%